ARTICLE | Strategy

As promised, DNXX pulls the plug

October 11, 1993 7:00 AM UTC

The costs of developing recombinant hemoglobin are giving at least some investors and companies pause.

DNX Corp. last week said it is dropping its program for developing a blood substitute from transgenic pigs, after having announced earlier that it wouldn't continue the program without a partner. "We set up some guidelines for ourselves very early on and we set a deadline that if we didn't have a partner on board we'd curtail the program," said Paul Schmitt, president and CEO...